 |
This article may require cleanup to meet Wikipedia's quality standards. Please improve this article if you can. (May 2009) |
| Type | Inc. |
|---|---|
| Headquarters | Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo) |
| Website | [1] |
Chugai Pharmaceutical Co., Ltd. is a subsidiary drug manufacturer operating in Japan controlled by Hoffmann–La Roche who owns a 52% majority of the company. Previous to Roche's takeover in 2002, Chugai was a pioneering discoverer of many important pharmaceutical compounds.
Crowning achievements and collaborations
- 1961 developed patents for synthesis vitamin A)
- 1995 acute promyelocytic sphere of drug treatment leukemia "BESANOIDO" was released.
- 1996 anti-viral chemotherapeutic agent "HAIBIDDO" released (HIV reverse transcriptase inhibitor)
- 1997 HIV protease inhibitor "INBIRAZE" released
- 1999 immunosuppressive agent "SERUSEPUTO" released
- 2000 Release of an antiemetic drug developed to combat the side effects of chemotherapy
- 2001 Produced an anti-influenza virus "Tamiflu" (Roche)
- 2001 Discovered a malignant lymphoma target molecule "RITSUKISAN"
- 2001 Released "Herceptin," a novel breast cancer therapeutic
Other notable developments
Scientists at Chugai discovered an erythromycin-derived motilin agonist called Mitemcinal (aka GM-611 or 3'-N-dimethyl-11-deoxy-3'-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycin.) Mitemcinal was believed to have strong prokinetic properties, similar to its parent molecule, but lack antibiotic properties. Presently, erythromycin is commonly used off-label for gastric motility indications such as Gastroparesis. If Mitemcinal can be shown to be as effective a prokinetic agent, it would represent a significant advance in the GI field as treatment with this drug would not carry the risk of unintentional selection of antibiotic-resistant bacteria.
External links
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
